1	Hypertension Trends and Disparities over Twelve Years in a Large Health System:
2	Leveraging the Electronic Health Records
3	Running Title: Hypertension Trends in a Health System
4	John E. Brush, Jr., MD* ^{1,2} , Yuan Lu, ScD* ^{3,4} , Yuntian Liu, MPH ³ , Jordan R. Asher,
5	MD, MS ¹ , Shu-Xia Li, PhD ³ , Mitsuaki Sawano, MD ³ , Patrick Young, PhD ⁴ , Wade L. Schulz,
6	MD ⁴ , Mark Anderson, AS ¹ , John S. Burrows, MBA ¹ , Harlan M. Krumholz, MD, SM ^{3,6,7}
7	Word Count (text only): 3120
8	Affiliation of Authors: ¹ Sentara Health, ² Eastern Virginia Medical School, Norfolk, VA;
9	³ Center for Outcomes Research and Evaluation, Yale-New Haven Hospital; ⁴ Department of
10	Laboratory Medicine, Yale School of Medicine; ⁵ Department of Biostatistics, Yale School of
11	Public Health; ⁶ Section of Cardiovascular Medicine, Department of Internal Medicine (HMK)
12	and ⁷ Department of Health Policy and Management, New Haven, CT.
13	
14	*Contributed equally as Co-First Authors.
15	Correspondence:
16	John E. Brush, Jr., MD
17	Sentara Health and Eastern Virginia Medical School
18	835 Glenrock Road, Suite 220
19	Norfolk, VA 23502
20	Telephone: (757) 261-0700
21	Fax: (757) 261-0701
22	Email: jebrush@sentara.com

23	Key Points
24	Question: Can a large regional health system leverage the electronic health record to analyze
25	hypertension trends and disparities to drive improvement?
26	Findings: We analyzed 1,376,325 patients over 12 years and found that age-adjusted
27	hypertension prevalence increased by approximately 5%. Age-adjusted hypertension control
28	rates were in the 70% range and remained stable. Non-Hispanic Black patients represented 25%
29	of our specific regional population and had 12-14% higher hypertension prevalence rates, higher
30	mean age-adjusted systolic and diastolic blood pressure, and lower hypertension control rates
31	compared with other racial groups.
32	Meaning: Real world data can provide actionable insights about hypertension and disparities in
33	a specific region that could inform regional system strategies and initiatives for improvement.
34	

36	Abstract
37	Background: The digital transformation of medical data enables health systems to
38	leverage real-world data (RWD) from electronic health records (EHR) to gain actionable insights
39	for improving hypertension care.
40	Methods: We performed a serial cross-sectional analysis of outpatients of a large
41	regional health system from 2010 to 2021. Hypertension was defined by systolic blood pressure
42	$(SBP) \ge 140 \text{ mmHg or diastolic blood pressure (DBP)} \ge 90 \text{ mmHg})$ or recorded treatment with
43	anti-hypertension medications. We evaluated four methods of using blood pressure
44	measurements in the EHR to define hypertension.
45	The primary outcomes were age-adjusted prevalence rates and age-adjusted control rates.
46	Secondary outcomes were age-adjusted mean SBP and DBP and age-adjusted proportion of
47	patients with a searchable diagnosis code of hypertension in the EHR.
48	Results: Hypertension prevalence varied depending on the definition used, ranging from
49	36.5% to 50.9% initially and increasing over time by approximately 5%, regardless of the
50	definition used. Control rates ranged from 61.2% to 71.3% initially, rose during 2018-2019 and
51	fell during 2020-2021. The proportion of patients with a hypertension diagnosis ranged from
52	45.5% to 60.2% initially and improved during the study period. Non-Hispanic Black patients
53	represented 25% of our regional population and consistently had higher prevalence rates, higher
54	mean SBP and DBP and lower control rates compared with other racial and ethnic groups.
55	Conclusion: In a large regional health system, we leveraged the EHR to provide real-
56	world insights. The findings largely reflected national trends but showed distinctive regional
57	demographics and findings. The findings have provided opportunities for improvement, with

- 58 prevalence increasing, a quarter of the patients not controlled, and marked disparities. This
- 59 approach could be emulated by regional health systems seeking to improve hypertension care.

1

Introduction

Hypertension is a persistent and challenging health problem in the United States,
estimated to affect almost half of adult Americans.¹ Of patients with hypertension, approximately
half have uncontrolled blood pressure (BP),² which disproportionately affects African
Americans.²⁻⁴ Improving the detection and treatment hypertension is a national priority and
offers an important opportunity to modify the risk for cardiovascular disease and stroke and to
address a major racial disparity.⁵

8 A 2014 advisory from the American College of Cardiology, American Heart Association 9 and the US Centers for Disease Control and Prevention called for health system approaches for addressing hypertension.⁶ System-wide strategies, along with improvements at the clinician and 10 patient level, could help optimize BP control and effectively modify the risk associated with 11 hypertension.^{6.7} To help design health system strategies, more information is needed to 12 characterize hypertension trends and identify opportunities for improvement at the regional 13 14 health system level, ideally utilizing readily available real-world evidence from the electronic health record (EHR) systems. 15

There are opportunities to broaden the ways a regional health system might use EHR data to investigate hypertension. Converting EHR data into a common data model can provide a more agile analytical platform, which could enable a health system to take advantage of their longterm data, explore various analytical methods, and evaluate trends and demographics that may be unique to a health system's region. Analysis of data at the regional level could enable customized regional initiatives to improve hypertension care.

Accordingly, we leveraged the EHR from a large health system caring for a diverse
population to evaluate performance in the care of patients with hypertension.⁸ EHR data over 12

24	years were transformed into a harmonized and validated data set that has enabled a serial cross-
25	sectional analysis of hypertension in a large regional population. ⁹ We specifically sought to
26	identify trends using various operational hypertension definitions to investigate disparities and
27	opportunities for improvement.
28	Methods
29	Data Source
30	This retrospective observational study was performed at a large non-profit integrated
31	healthcare system in Virginia and Northeastern North Carolina. The system began using a
32	centralized EHR system designed by the Epic Corporation in 2007. In 2021, the health system
33	began extracting key clinical data from its EHR and transforming the data into a harmonized data
34	platform using the Observational Medical Outcomes Partnership (OMOP) common data model
35	version 5.3. ⁹
36	Study Population
37	The overall study population consisted of all adult patients (≥ 18 years old) who had at
38	least 1 outpatient blood pressure reading recorded between January 1st, 2010, and December
39	31st, 2021. Emulating the NHANES study, ² we conducted a serial cross-sectional study by
40	independently analyzing the data in 2-year cycles from 2010-2011 to 2020-2021. In contrast to
41	the defined clinical protocols of NHANES, our real-world data approach required defining
42	computational protocols to analyze recorded BP readings in the EHR to create operational
43	definitions of hypertension.
44	BP readings were first analyzed at the visit level. If more than one BP reading was taken
45	during a visit, the first reading was disregarded and the mean of the remaining BP readings from

46 the visit defined the visit BP measurement. If multiple outpatient visits occurred for a patient on

47 a specific date, we calculated the mean of the visit BP measurements and used the mean as the48 visit BP measurement for that date.

49 **Definition of Hypertension**

In each 2-year cycle, a patient was classified as having hypertension according to the definitions listed below using either an elevated visit BP measurement, or use of at least one first line anti-hypertension medication recorded during the 2-year cycle, like NHANES.² BP elevation was defined as a systolic blood pressure (SBP) \ge 140 mm Hg, or diastolic blood pressure (DBP) \ge 90 mm Hg. First-line anti-hypertension medications were defined according to the 2017 AHA/ACC hypertension guideline¹⁰ and are listed with their associated OMOP concept

identification numbers in eTable 1.

57 We evaluated four operational hypertension definitions using four different methods for 58 incorporating recorded BP measurement into the definition: 1) using at least one elevated visit 59 BP measurement during a 2-year cycle, 2) using the first visit BP measurement during a 2-year cycle, 3) using a single randomly chosen visit BP measurement during a 2-year cycle, or 4) using 60 61 at least two elevated visit BP measurements during a 2-year cycle. Our rationale for using these 62 different operational hypertension definitions was to provide definitions that are comparable with 63 other studies and guideline recommendations. For example, our third definition would be comparable to the NHANES study,² and our fourth definition would be comparable to the 64 generally accepted guideline definition.¹⁰ 65

66

67 **Definitions of Outcomes**

68 Primary outcomes were age-adjusted hypertension prevalence and age-adjusted rates of
69 BP control during each 2-year cycle. BP control was defined at the patient level as a mean SBP <

70 140 mmHg and mean DBP < 90 mmHg during a 2-year cycle. To adjust for differences in age 71 distribution among the 2-year study cycles, direct standardization was employed using two 72 different standards. For age-adjustment of hypertension prevalence and average BP, the standard 73 was the average age distribution of all adults across all study cycles, while for age-adjustment of 74 other outcome measures, the standard was average age distribution of adults with hypertension 75 across all study cycles. The age categories used for standardization were: 18-44 years, 45-64 76 years, 65-74 years, and 75 years or older. The proportions used for age-adjustment of all patients 77 and of hypertension patients for each operational hypertension definition are listed in eTable 2. 78 Secondary outcome measures were the age-adjusted mean SBP and DBP for all patients 79 and for hypertensive patients, and the age-adjusted proportions of patients who were labelled with a searchable diagnosis code of hypertension in the EHR during a 2-year cycle. The coded 80 81 diagnoses of hypertension and the corresponding OMOP concept identification numbers listed in 82 eTable 3).

83

84 Statistical Analysis

85 Descriptive statistics were used to characterize the overall study population and the 86 populations from each 2-year cycle, and graphical representations were used to demonstrate 87 temporal trends. The generalized estimation equation (GEE) method was applied to assess the 88 predictors of different outcomes while accounting for the fact that multiple observations might 89 have been available for the same individuals at different cycles. Specifically, an exchangeable 90 within-person working correlation structure was specified in each GEE model and 95% 91 confidence intervals were calculated using a robust variance estimator. Models used to evaluate 92 dichotomous outcomes included a specification for the binomial distribution of the dependent

93	variable, and models used to evaluate continuous outcomes included a specification for the
94	Gaussian distribution of the dependent variable. The independent variables included cycle, sex,
95	race and ethnicity, and age group, and each variable was treated as categorical in the GEE model.
96	To simplify the analysis and avoid multiple comparisons, in the GEE modeling section, we only
97	used the operational hypertension definition that used BP measurement from a single randomly
98	chosen visit during a 2-year cycle. All statistical tests were 2-sided, with a level of significance
99	of 0.05. Data collection using the OMOP model was conducted with the Microsoft SQL Server
100	and data analysis was performed using R (version 4.2.3). The study was approved by the
101	Institutional Review Board at Eastern Virginia Medical School. The study was reported
102	following the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology)
103	reporting guidelines. ¹¹
104	Results
105	
105	Population Characteristics
105	A total of 1,376,325 unique adults met the overall study inclusion criteria. The
105 106 107	A total of 1,376,325 unique adults met the overall study inclusion criteria. The demographics of the overall study population in each 2-year cycle are shown in Table 1. Each 2-
105 106 107 108	A total of 1,376,325 unique adults met the overall study inclusion criteria. The demographics of the overall study population in each 2-year cycle are shown in Table 1. Each 2-year cycle was analyzed independently, and individual patients could appear in one or more 2-
105 106 107 108 109	A total of 1,376,325 unique adults met the overall study inclusion criteria. The demographics of the overall study population in each 2-year cycle are shown in Table 1. Each 2- year cycle was analyzed independently, and individual patients could appear in one or more 2- year cycles, depending on the care they received. Thus, the number of patients in the six 2-year
105 106 107 108 109 110	A total of 1,376,325 unique adults met the overall study inclusion criteria. The demographics of the overall study population in each 2-year cycle are shown in Table 1. Each 2- year cycle was analyzed independently, and individual patients could appear in one or more 2- year cycles, depending on the care they received. Thus, the number of patients in the six 2-year cycles varied and ranged from 395,859 patients to 631,892 patients per 2-year cycle. The
105 106 107 108 109 110 111	A total of 1,376,325 unique adults met the overall study inclusion criteria. The demographics of the overall study population in each 2-year cycle are shown in Table 1. Each 2- year cycle was analyzed independently, and individual patients could appear in one or more 2- year cycles, depending on the care they received. Thus, the number of patients in the six 2-year cycles varied and ranged from 395,859 patients to 631,892 patients per 2-year cycle. The numbers of outpatient visits and outpatient BP measurements per patient during a 2-year cycle
105 106 107 108 109 110 111 112	A total of 1,376,325 unique adults met the overall study inclusion criteria. The demographics of the overall study population in each 2-year cycle are shown in Table 1. Each 2- year cycle was analyzed independently, and individual patients could appear in one or more 2- year cycles, depending on the care they received. Thus, the number of patients in the six 2-year cycles varied and ranged from 395,859 patients to 631,892 patients per 2-year cycle. The numbers of outpatient visits and outpatient BP measurements per patient during a 2-year cycle were relatively constant during the study period. The median number of outpatient visits per
105 106 107 108 109 110 111 112 113	A total of 1,376,325 unique adults met the overall study inclusion criteria. The demographics of the overall study population in each 2-year cycle are shown in Table 1. Each 2-year cycle was analyzed independently, and individual patients could appear in one or more 2-year cycles, depending on the care they received. Thus, the number of patients in the six 2-year cycles varied and ranged from 395,859 patients to 631,892 patients per 2-year cycle. The numbers of outpatient visits and outpatient BP measurements per patient during a 2-year cycle were relatively constant during the study period. The median number of outpatient visits per patient was 2 during 2010-2011 and 3 during the remaining 2-year cycles. The median number of
105 106 107 108 109 110 111 112 113 114	A total of 1,376,325 unique adults met the overall study inclusion criteria. The demographics of the overall study population in each 2-year cycle are shown in Table 1. Each 2- year cycle was analyzed independently, and individual patients could appear in one or more 2- year cycles, depending on the care they received. Thus, the number of patients in the six 2-year cycles varied and ranged from 395,859 patients to 631,892 patients per 2-year cycle. The numbers of outpatient visits and outpatient BP measurements per patient during a 2-year cycle were relatively constant during the study period. The median number of outpatient visits per patient was 2 during 2010-2011 and 3 during the remaining 2-year cycles. The median number of outpatient BP measurements per patient was 5 during 2012-2013 and 2018-2019 and was 4
105 106 107 108 109 110 111 112 113 114 115	A total of 1,376,325 unique adults met the overall study inclusion criteria. The demographics of the overall study population in each 2-year cycle are shown in Table 1. Each 2- year cycle was analyzed independently, and individual patients could appear in one or more 2- year cycles, depending on the care they received. Thus, the number of patients in the six 2-year cycles varied and ranged from 395,859 patients to 631,892 patients per 2-year cycle. The numbers of outpatient visits and outpatient BP measurements per patient during a 2-year cycle were relatively constant during the study period. The median number of outpatient visits per patient was 2 during 2010-2011 and 3 during the remaining 2-year cycles. The median number of outpatient BP measurements per patient was 5 during 2012-2013 and 2018-2019 and was 4 during the remaining 2-year cycles.

116	Among all patients, the mean age-adjusted SBP ranged from 125.1 to 127.0 mm Hg and
117	the mean age-adjusted DBP ranged from 74.4 to 76.0 mm Hg (Table 1). Mean SBP and DBP
118	among all patients showed an upward trend during the time of study.
119	
120	Hypertension Prevalence and Disparities
121	The demographics of the hypertensive patients varied slightly depending on the
122	operational hypertension definition. The demographics of hypertensive patients (using the
123	random BP measurement definition, which is comparable to the NHANES study) are shown in
124	eTable 4.
125	The age-adjusted hypertension prevalence rates over the 12-year study period for each
126	operational hypertension definition are shown in Figure 1. Depending on the operational
127	hypertension definition, the hypertension prevalence rates ranged from 36.5% to 50.9% and
128	prevalence increased by about 5% over the study period regardless of the operational
129	hypertension definition.
130	Non-Hispanic Black patients consistently showed 12-14% higher age-adjusted
131	hypertension prevalence rates compared with the non-Hispanic White patients (OR 2.03, [2.02,
132	2.04], P <0.001, Figure 2). Hypertension prevalence rates were progressively higher by age
133	group, peaking at 80% in patients >75 years old during 2020-2021 (eFigure 1). Men consistently
134	showed approximately 7% higher hypertension prevalence rates (OR 1.41, [1.40, 1.42], P
135	<0.001, eFigure 2).
136	The proportions of hypertensive patients defined by elevated BP only, by use of a first-
137	line antihypertensive medication only, or by both are shown in eFigure3. For all operational

hypertension definitions, the proportions of hypertensive patients defined by medication usage orcombination of medication usage and elevated BP increased during the study period.

140

141 Blood Pressure Control Rates Among Patients with Hypertension and Disparities

Among patients with hypertension, the age-adjusted BP control rates during the study

143 period ranged from 61.2% to 73.3%, depending on the operational hypertension definition

144 (Figure 3). The trend in BP control rates exhibited an initial increase from 2010-2011 to 2014-

145 2015, followed by a decline in 2016-2017. Thereafter, the control rates rose again from 2018-

146 2019, only to decline once more in 2020-2021. The age-adjusted BP control rates were

147 consistently about 3% lower in men (OR 0.89, [0.88, 0.90], P<0.001, eFigure 4) and consistently

about 5-7% lower in non-Hispanic Black patients as compared with non-Hispanic White patients

149 (OR 0.77, [0.76, 0.78], P<0.001, eFigure 5).

Among hypertension patients, the mean age-adjusted SBP ranged from 132.3 to 135.4 mmHg and mean age-adjusted DBP ranged from 76.8 to 78.8 mmHg (eFigure 6). Mean BP was relatively unchanged during the study timeframe regardless of the operational hypertension definition. Age-adjusted mean BP was consistently higher in non-Hispanic Black patients as compared with other non-Hispanic White patients (SBP: +2.61 [2.55, 2.67]; DBP: +1.31 [1.28, 1.35]; P < 0.001 for both, eFigure 7).

- 156
- 157

Coded Diagnosis Rates Among Patients with Hypertension and Disparities

Among patients with hypertension, the age-adjusted proportion of patients labelled in the EHR with a coded diagnosis of hypertension ranged from 45.5% to 68.6%, again depending on the operational hypertension definition (Figure 4). The proportion of patients diagnosed with

- 161 hypertension, as indicated by coded diagnoses, exhibited an initial increase from 2010-2011 to
- 162 2014-2015, followed by a decline in 2016-2017. Thereafter, the proportions rose again in 2020-
- 163 2021. The proportion of patients with a coded diagnosis of hypertension was highest in
- 164 hypertension groups defined by 2 or more BP measurements than in groups defined by the other
- definitions. The proportion of patients with hypertension with a coded diagnosis of hypertension
- 166 was similar in women and men. Rates of receiving a coded diagnosis were consistently about 5%
- 167 higher in non-Hispanic Black patients (OR 1.26 [1.25, 1.27], P<0.001) and Asian patients (OR
- 168 1.31 [1.28, 1.35], P<0.001), compared with White and Hispanic patients (eFigure 8).
- 169
- 170

1	7	1
-	1	-

Discussion

172 In this serial cross-sectional study, we leveraged EHRs of a large health system to 173 analyze regional trends in hypertension using various operational hypertension definitions. We 174 showed a marked increase in age-adjusted hypertension prevalence rates, modest age-adjusted 175 BP control rates, and relatively low but upwardly trending age-adjusted rates of coding 176 hypertension in the EHR during the 12 years of study. In addition, we noted important disparities 177 in age-adjusted hypertension prevalence rates, age-adjusted BP control rates, and age-adjusted mean BP levels that stayed consistent over time. The age-adjusted hypertension prevalence rates 178 179 were 12-14% higher in non-Hispanic Black patients, 7% higher in men, and progressively higher 180 by age group throughout the study period. This study demonstrates the ability to observe hypertension trends and disparities at a 181 182 regional health system level using real-world data, which could greatly facilitate locally designed 183 system-level interventions to address hypertension and racial disparities. We were able to create 184 an agile analytical data platform that enabled a comparison of a variety of operational 185 hypertension definitions and an evaluation of how age, sex, and race/ethnicity affect 186 hypertension trends. Our analytical data platform enabled examination of multiple operational 187 hypertension definitions and we demonstrated substantial differences in outcomes, depending on 188 the sensitivity of the hypertension definition. 189 Our study demonstrated a steady rise of about 5% in the age-adjusted hypertension 190 prevalence rates throughout the study period, regardless of the operational hypertension 191 definition. Increases in hypertension prevalence rates were seen in all age groups, both sexes,

and in all race/ethnicity groups.

193 The average age of patients and the age adjusted mean SBP and DBP increased during 194 the study period, which may have contributed to the increase in hypertension prevalence rates. 195 The increase in hypertension prevalence rates did not appear to be artifactually affected by the 196 frequency of outpatient visits or BP measurements.

Our definition of hypertension included whether patients were prescribed first-line antihypertension medications, which may have also contributed to the increase in hypertension prevalence rates. The proportion of patients who were defined as hypertensive by the medication-use criterion increased during the 2012-2013, 2018-2019 and 2020-20201 2-year cycles, possibly due to changing guidelines for hypertension. The 2017 ACC/AHA published guidelines recommended a lower BP goal which could have caused more patients to receive firstline antihypertensive medications and could have affected the hypertension prevalence rates

during 2018-2019 and 2020-2021.¹⁰

205 The age-adjusted proportion of patients with controlled BP rose from 61-71% in 2010-206 2011 to 64-73% in 2014-2015, fell in 2016-2017, rose again to 66-73% in 2018-2019, and fell in 207 62-68% in 2020-2021. The pattern was consistent among patients defined by all 4 operational 208 hypertension definitions. Non-Hispanic Blacks had BP control rates that were consistently about 209 5% lower than Whites. The rise in control rates in all groups during 2018-2019 could be 210 explained by the 2017 ACC/AHA guideline recommendations for tighter BP control.¹⁰ The fall 211 in control during 2020-2021 may have been caused by changes in healthcare associated with the 212 COVID-19 pandemic.

The proportion of patients with a coded diagnosis of hypertension among patients with hypertension increased during the study period except during 2016-2017 and the trends were similar in all 4 operational hypertension definition groups. There were no differences by sex.

216 Non-Hispanic Blacks and Asians were 6-10% more likely to have a coded diagnosis of 217 hypertension as compared with other race/ethnicity groups. Interestingly, non-Hispanic Black 218 patients were significantly more likely to have hypertension by all the operational hypertension 219 definitions and less likely to have BP controlled, even though they were more likely to have been 220 labelled in the EHR with a coded diagnosis of hypertension. 221 Our results from a regional health system provide supplemental information to the 222 national estimates reported by the National Health and Nutrition Examination Survey 223 (NHANES). Using a comparable operational hypertension definition (a single random visit BP 224 measurement), our age-adjusted hypertension prevalence rates are higher (41.1% to 46.1%) and 225 increased steadily as compared with NHANES which reported prevalence rates that were lower and remained constant (30% to 32%).² Our BP control rates (61.2% to 65.9%) were also higher 226 227 than those reported by NHANES (31.8% to 53.8%). These differences may be because our study 228 population was derived from patients exposed to a healthcare system rather than subjects 229 randomly selected from the general population. Importantly, the proportion of non-Hispanic 230 Blacks in our study was roughly twice that from the NHANES study, reflecting the 231 demographics of our region, which may have increased the hypertension prevalence rates. 232 Studies have suggested that hypertension prevalence based on methods using electronic health records could be underestimated.¹² In our study, we used the EHR, but we defined 233 234 hypertension based on measurement of BP, rather than based on the coded diagnosis of 235 hypertension, which appears to have overcome the potential of under-reporting hypertension 236 using the EHR. 237 Our hypertension control rates were similar to those reported by the PCORnet Blood

238 Pressure Control Laboratory, which reported an average BP control rate of 62%.¹³ Their findings

239	from 25 health systems showed different demographics than our regional analysis, with Black
240	patients only comprising 15% of their population, as compared to approximately 30% of the
241	hypertensive patients in our study. While nationwide studies are informative, limiting the
242	analysis to a single regional health system may provide actionable insights regarding disparities
243	that are more relevant locally, based on the demographics of that regional health system.
244	Banerjee et al measured the hypertension coding rate in 251,590 patients defined
245	hypertension by 2 or more BP readings ≥140/90 mm Hg and/or antihypertensive medications
246	prescribed during the study period. Among those patients, the coded diagnosis rate was 62.9%,
247	very similar to our finding among patients with a comparable operational hypertension
248	definition. ¹²
249	Our study has recognized strengths and limitations. Our approach of analyzing real-world
250	data from a single health system is practical and feasible, and the results are similar to the
251	multicenter approach of the PCORnet Blood Pressure Control Laboratory. ¹⁴ Our data platform
252	allows rapid evaluation of populations at scale and could be a source of continuing evaluation
253	with planned periodic additions to the data base, ^{15,16} providing a powerful tool for generating
254	actionable insights from real-world data. ^{17,18} This data resource is an model of what could be a
255	useful generator of insights for a learning health system. ^{19,20}
256	A possible limitation of our study, as compared with the NHANES approach, ² however,
257	is that BP was obtained in the usual care setting, rather than through a rigorous protocolized
258	approach. Although clinicians expect and often demand accurate BP measurements in usual care
259	settings, the BP measurements in real-world settings may be less accurate than in the
260	protocolized setting of a prospective research study. ²¹ Also, the coded diagnosis of hypertension
261	in the EHR could have been affected by recall bias and other sources of possible coding error. ¹⁵

262	In conclusion, we were able to use real-world EHR data to establish hypertension
263	prevalence rates, control rates, and diagnostic coding rates in a large population using the EHR
264	from a large regional health system, showing important trends and opportunities to address racial
265	disparities. Our study may provide a model for other health systems seeking to improve
266	hypertension care at a regional health system level and may lead to further research on how to
267	use real-world data and computational approaches for addressing hypertension.
268	Conflicts of Interest and Financial Disclosures
269	In the past three years, Dr. Krumholz received expenses and/or personal fees from
270	UnitedHealth, Element Science, Aetna, Reality Labs, Tesseract/4Catalyst, F-Prime, the
271	Siegfried and Jensen Law Firm, Arnold and Porter Law Firm, and Martin/Baughman Law
272	Firm. He is a co-founder of Refactor Health and HugoHealth, and is associated with
273	contracts, through Yale New Haven Hospital, from the Centers for Medicare & Medicaid
274	Services and through Yale University from Johnson & Johnson. Dr. Brush receives royalties
275	from Dementi Milestone Publishing for the book "The Science of the Art of Medicine: A
276	Guide to Medical Reasoning." Dr. Schulz received expenses and/or personal fees from
277	HugoHealth, Abbott, Instrumentation Laboratories, and Detect, Inc., and is a cofounder of
278	Refactor Health. The other authors report no disclosures.
279	
280	

282		References
283	1.	Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, Boehme
284		AK, Buxton AE, Carson AP, Commodore-Mensah Y, Elkind MSV, Evenson KR,
285		Eze-Nliam C, Ferguson JF, Generoso G, Ho JE, Kalani R, Khan SS, Kissela BM,
286		Knutson KL, Levine DA, Lewis TT, Liu J, Loop MS, Ma J, Mussolino ME,
287		Navaneethan SD, Perak AM, Poudel R, Rezk-Hanna M, Roth GA, Schroeder EB,
288		Shah SH, Thacker EL, VanWagner LB, Virani SS, Voecks JH, Wang NY, Yaffe K
289		and Martin SS. Heart Disease and Stroke Statistics-2022 Update: A Report From the
290		American Heart Association. Circulation. 2022;145:e153-e639.
291	2.	Muntner P, Hardy ST, Fine LJ, Jaeger BC, Wozniak G, Levitan EB and Colantonio
292		LD. Trends in Blood Pressure Control Among US Adults With Hypertension, 1999-
293		2000 to 2017-2018. JAMA. 2020;324:1190-1200.
294	3.	Clark D, 3rd, Colantonio LD, Min YI, Hall ME, Zhao H, Mentz RJ, Shimbo D,
295		Ogedegbe G, Howard G, Levitan EB, Jones DW, Correa A and Muntner P.
296		Population-Attributable Risk for Cardiovascular Disease Associated With
297		Hypertension in Black Adults. JAMA Cardiol. 2019;4:1194-1202.
298	4.	Lu Y, Wang Y, Spatz ES, Onuma O, Nasir K, Rodriguez F, Watson KE and
299		Krumholz HM. National Trends and Disparities in Hospitalization for Acute
300		Hypertension Among Medicare Beneficiaries (1999-2019). Circulation.
301		2021;144:1683-1693.
302	5.	Bundy JD, Li C, Stuchlik P, Bu X, Kelly TN, Mills KT, He H, Chen J, Whelton PK
303		and He J. Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and

304		Mortality: A Systematic Review and Network Meta-analysis. JAMA Cardiol.
305		2017;2:775-781.
306	6.	Go AS, Bauman MA, Coleman King SM, Fonarow GC, Lawrence W, Williams KA
307		and Sanchez E. An effective approach to high blood pressure control: a science
308		advisory from the American Heart Association, the American College of Cardiology,
309		and the Centers for Disease Control and Prevention. J Am Coll Cardiol.
310		2014;63:1230-1238.
311	7.	Jaffe MG, Lee GA, Young JD, Sidney S and Go AS. Improved blood pressure control
312		associated with a large-scale hypertension program. JAMA. 2013;310:699-705.
313	8.	Lu Y, Huang C, Mahajan S, Schulz WL, Nasir K, Spatz ES and Krumholz HM.
314		Leveraging the Electronic Health Records for Population Health: A Case Study of
315		Patients With Markedly Elevated Blood Pressure. J Am Heart Assoc.
316		2020;9:e015033.
317	9.	Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, Suchard MA,
318		Park RW, Wong IC, Rijnbeek PR, van der Lei J, Pratt N, Noren GN, Li YC, Stang
319		PE, Madigan D and Ryan PB. Observational Health Data Sciences and Informatics
320		(OHDSI): Opportunities for Observational Researchers. Stud Health Technol Inform.
321		2015;216:574-8.
322	10.	Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison
323		Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ,
324		Muntner P, Ovbiagele B, Smith SC, Jr., Spencer CC, Stafford RS, Taler SJ, Thomas
325		RJ, Williams KA, Sr., Williamson JD and Wright JT, Jr. 2017
326		ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for

327	the Prevention, Detection, Evaluation, and Management of High Blood Pressure in
328	Adults: A Report of the American College of Cardiology/American Heart Association
329	Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71:e127-e248.
330	11. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP and
331	Initiative S. The Strengthening the Reporting of Observational Studies in
332	Epidemiology (STROBE) Statement: guidelines for reporting observational studies.
333	International journal of surgery. 2014;12:1495-1499.
334	12. Banerjee D, Chung S, Wong EC, Wang EJ, Stafford RS and Palaniappan LP.
335	Underdiagnosis of hypertension using electronic health records. Am J Hypertens.
336	2012;25:97-102.
337	13. Cooper-DeHoff RM, Fontil V, Carton T, Chamberlain AM, Todd J, O'Brien EC,
338	Shaw KM, Smith M, Choi S, Nilles EK, Ford D, Tecson KM, Dennar PE, Ahmad F,
339	Wu S, McClay JC, Azar K, Singh R, Faulkner Modrow M, Shay CM, Rakotz M,
340	Wozniak G and Pletcher MJ. Tracking Blood Pressure Control Performance and
341	Process Metrics in 25 US Health Systems: The PCORnet Blood Pressure Control
342	Laboratory. J Am Heart Assoc. 2021;10:e022224.
343	14. Pletcher MJ, Fontil V, Carton T, Shaw KM, Smith M, Choi S, Todd J, Chamberlain
344	AM, O'Brien EC, Faulkner M, Maeztu C, Wozniak G, Rakotz M, Shay CM and
345	Cooper-DeHoff RM. The PCORnet Blood Pressure Control Laboratory: A Platform
346	for Surveillance and Efficient Trials. Circ Cardiovasc Qual Outcomes.
347	2020;13:e006115.

348	15. Casey JA, Schwartz BS, Stewart WF and Adler NE. Using Electronic Health Records
349	for Population Health Research: A Review of Methods and Applications. Annu Rev
350	Public Health. 2016;37:61-81.
351	16. Schulz WL, Kvedar JC and Krumholz HM. Agile analytics to support rapid
352	knowledge pipelines. NPJ Digit Med. 2020;3:108.
353	17. Krumholz HM. Big data and new knowledge in medicine: the thinking, training, and
354	tools needed for a learning health system. Health Aff (Millwood). 2014;33:1163-70.
355	18. Krumholz HM. Inflection Point: Ideas for Accelerating Breakthroughs and Improving
356	Cardiovascular Health. Circ Cardiovasc Qual Outcomes. 2020;13:e007615.
357	19. Greene SM, Reid RJ and Larson EB. Implementing the learning health system: from
358	concept to action. Ann Intern Med. 2012;157:207-10.
359	20. Foraker RE, Benziger CP, DeBarmore BM, Cene CW, Loustalot F, Khan Y,
360	Anderson CAM, Roger VL, American Heart Association Council on E, Prevention,
361	Council on Arteriosclerosis T, Vascular B, Council on L and Cardiometabolic H.
362	Achieving Optimal Population Cardiovascular Health Requires an Interdisciplinary
363	Team and a Learning Healthcare System: A Scientific Statement From the American
364	Heart Association. Circulation. 2021;143:e9-e18.
365	21. Muntner P, Shimbo D, Carey RM, Charleston JB, Gaillard T, Misra S, Myers MG,
366	Ogedegbe G, Schwartz JE, Townsend RR, Urbina EM, Viera AJ, White WB and
367	Wright JT, Jr. Measurement of Blood Pressure in Humans: A Scientific Statement
368	From the American Heart Association. Hypertension. 2019;73:e35-e66.
369	

371 Table 1. Demographic characteristics and mean systolic blood pressure (SBP) and mean

2-year Cycle	2010-2011	2012-2013	2014-2015	2016-2017	2018-2019	2020-2021
Patients	395,859	429,754	466,692	631,892	608,497	619,023
Sex						
Female	231,203	254,610	275,386	370,352	355,759	362,140
	(58%)	(59%)	(59%)	(59%)	(58%)	(59%)
Male	164,625	175,130	191,306	261,540	252,736	256,874
	(42%)	(41%)	(41%)	(41 %)	(42%)	(41%)
Race/Ethnicity						
Non-Hispanic	99,779	109,183	122,477	142,447	135,880	146,162
Black	(25%)	(25%)	(26%)	(23%)	(22%)	(24%)
Non-Hispanic	259,665	282,167	305, 112	438,170	423,892	423, 186
White	(66%)	(66%)	(65%)	(69%)	(70%)	(68%)
Hispanic/Latino	7,342	11,549	13,060	19,449	19,691	21,297
-	(1.9%)	(2.7%)	(2.8%)	(3.1%)	(3.2%)	(3.4%)
Asian	7,616	9,294	10,406	12,698	12,834	13,363
	(1.9%)	(2.2%)	(2.2%)	(2.0%)	(2.1%)	(2.2%)
Unknown	21,457	17,561	15,637	19,128	16,200	15,015
	(5.4%)	(4.1%)	(3.4%)	(3.0%)	(2.7%)	(2.4%)
Mean Age (SD)	51.0 (18.1)	51.5 (18.2)	52.3 (18.2)	52.9 (18.4)	54.6 (18.2)	55.3 (18.2)
Age Group						
18-44	142,539	151,749	158,628	210,073	182,608	181,485
	(36%)	(35%)	(34%)	(33%)	(30%)	(29%)
45-64	156,016	165,571	178, 135	234,314	224,434	221,173
	(39%)	(39%)	(38%)	(37%)	(37%)	(36%)
65-74	54,364	64,801	76,065	109,058	114,851	124,125
	(14%)	(15%)	(16%)	(17%)	(19%)	(20%)
>75	42,940	47,633	53,864	78,447	86,604	92,240
	(11%)	(11%)	(12%)	(12%)	(14%)	(15%)
Mean SBP (SD)	125.2 (14.9)	124.8 (14.8)	125.1 (14.8)	126.1 (14.8)	126.1 (14.2)	127.5 (14.6)
Mean DBP (SD)	74.7 (9.4)	74.4 (9.2)	74.7 (9.1)	75.5 (9.0)	75.3 (8.7)	75.8 (8.8)

diastolic blood pressure (DBP) of all patients in each 2-year cycle.

373 SD=standard deviation

375

Figures

Figure 1. Age-adjusted hypertension prevalence rates in each 2-year cycle by operational



1BP+ I First-line Med First BP I First-line Meds Random BP I First-line Meds 2BP+ I First-line Meds 609 52.6% 53.2 50.9 Hypertension Prevalence Rates 46.3% 43.7% 43.6% 41.1% 41.3% 37.6% 38.65 36.5% 36.1% 30% 10–11 12–13 14–15 16–17 18–19 20–21 **2–Year Cycle** 10-11 12-13 14-15 16-17 18-19 20-21 10-11 12-13 14-15 16-17 18-19 20-21 378 379 1BP+=1 elevated blood pressure (BP) measurement, 2BP+= at least 2 elevated measurements. 380 381

Figure 2. Age-adjusted hypertension prevalence rates by race/ethnicity in each 2-year cycle by

383 operational hypertension definition.



Figure 3. Age-adjusted blood pressure control rates in each 2-year cycle by operational



388 hypertension definition.



Figure 4. Age-adjusted hypertension coding rates in each 2-year cycle by operational



394 hypertension definition.